Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023 DOI Creative Commons

Zhilan Huang,

Tingyi Xie,

Wei Xie

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: July 31, 2024

Background Lung cancer (LC) is one of the most common malignant tumors in world and leading cause cancer-related deaths, which seriously threatens human life health as well brings a heavy burden to society. In recent years, tumor microenvironment (TME) has become an emerging research field hotspot affecting pathogenesis therapeutic approaches. However, date, there been no bibliometric analysis lung from 2014 2023.This study aims comprehensively summarize current situation development trends perspective. Methods The publications about 2023 were extracted Web Science Core Collection (WoSCC). Microsoft Excel, Origin, R-bibliometrix, CiteSpace, VOSviewer software are used scientifically analyze data. Results Totally, 763 identified this study. A rapid increase number was observed after 2018. More than 400 organizations published these 36 countries or regions. China United States have significant influence field. Zhou, CC Frontiers Immunology productive authors journals respectively. Besides, frequently cited references those on pathogenesis, clinical trials, treatment modalities. It suggests that novel models mainly based TME components, such cancer-associated fibroblasts (CAFs) may lead future trends. Conclusions still beginning stages. Gene expression, molecular pathways, modalities, detection technologies widely studied by researchers. This first trend regarding over last decade. result our provides updated perspective for scholars understand key information cutting-edge hotspots field, identify directions.

Language: Английский

Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation DOI Creative Commons

Yang Gao,

Jianan Li,

Wenfeng Cheng

et al.

Cancer Cell, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

38
Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer DOI Creative Commons
Katey S.S. Enfield, Emma Colliver, Claudia Lee

et al.

Cancer Discovery, Journal Year: 2024, Volume and Issue: 14(6), P. 1018 - 1047

Published: April 6, 2024

Abstract Understanding the role of tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs treatment-naïve early-stage using imaging mass cytometry TRACERx study (n = 81 patients/198 samples/2.3 million cells). In immune-hot adenocarcinomas, spatial niches T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for plasma B immune-excluded squamous cell carcinomas (LUSC). Immune-low were associated fibroblast barriers immune infiltration. The fourth archetype, characterized by sparse lymphocytes high tumor-associated neutrophil (TAN) infiltration, had spatially separated from vasculature exhibited low intratumor heterogeneity. TAN-high LUSC frequent PIK3CA mutations. tumors harbored recently expanded metastasis-seeding subclones a shorter disease-free survival independent stage. These findings delineate genomic, immune, physical surveillance implicate neutrophil-rich metastasis. Significance: This provides novel insights into organization TME context immunogenicity, heterogeneity, evolution. Pairing evolutionary history resolved suggests mechanistic hypotheses progression metastasis implications outcome treatment. article featured Selected Articles Issue, p. 897

Language: Английский

Citations

32
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome DOI Creative Commons
Layla Mathieson, Lilian Koppensteiner, David A. Dorward

et al.

British Journal of Cancer, Journal Year: 2024, Volume and Issue: 130(11), P. 1758 - 1769

Published: April 6, 2024

Abstract Background Cancer-associated fibroblasts (CAFs) are a dominant cell type in the stroma of non-small lung cancer (NSCLC). Fibroblast heterogeneity reflects subpopulations CAFs, which can influence prognosis and treatment efficacy. We describe subtypes CAFs NSCLC. Methods Primary human NSCLC resections were assessed by flow cytometry multiplex immunofluorescence for markers fibroblast activation allowed identification CAF subsets. Survival data analysed our cohort consisting 163 patients to understand prognostic significance Results identified five populations, termed S1-S5. CAF-S5 represents previously undescribed population, express FAP PDPN but lack myofibroblast marker αSMA, whereas CAF-S1 populations all three. spatially further from tumour regions then scRNA demonstrate an inflammatory phenotype. The presence or is correlated worse survival outcome NSCLC, despite curative resection, highlighting importance TCGA suggest predominance has poor across several types. Conclusion This study describes novel subset where its correlates outcome.

Language: Английский

Citations

21
Integrative analysis of Ewing’s sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy DOI Creative Commons
Fangzhou He, Jiuhui Xu, Fanwei Zeng

et al.

Cell Communication and Signaling, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 13, 2025

Ewing's sarcoma (EwS), a common pediatric bone cancer, is associated with poor survival due to lack of therapeutic targets for immunotherapy or targeted therapy. Therefore, more effective treatment options are urgently needed. Since novel immunotherapies may address this need, we performed an integrative analysis involving single-cell RNA sequencing, cell function experiments, and humanized models dissect the immunoregulatory interactions in EwS identify strategies optimizing immunotherapeutic efficacy. infiltrated by immunosuppressive myeloid populations, T B lymphocytes, natural killer cells. We found that SLC40A1 C1QA macrophages were prognosis, whereas CD8+ T-cell infiltration was good prognosis. A comparative paired samples revealed tumors chemotherapeutic response, presented increased antigen presentation reduced release protumor cytokines, cells cytotoxicity exhaustion. An interaction vast network identified MIF-CD74 as crucial target can simultaneously promote M2 polarization inhibit infiltration. Importantly, MIF blockade effectively reshaped tumor immune microenvironment, turning cold hot inhibiting growth. Our MIF/CD74 axis promising Ewing provides rationale immunotherapy.

Language: Английский

Citations

3
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures DOI Creative Commons
Florent Peyraud,

Jean-Philippe Guégan,

Christophe Rey

et al.

Cell Reports Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 101934 - 101934

Published: Feb. 1, 2025

Highlights•mTLSs are predictive of response to ICIs in NSCLC•Two CAF subsets within the TME key determinants primary resistance ICIs•FAP+αSMA+ CAFs correlate with inflammatory and exhaustion CD8+ T cells•MYH11+αSMA+ favor an immunosuppressive CD4+ Treg cell infiltrationSummaryEffectiveness immune checkpoint inhibitors (ICIs) non-small lung cancer (NSCLC) has been linked presence mature tertiary lymphoid structures (mTLSs) tumor microenvironment (TME). However, only a subset mTLS-positive NSCLC derives benefit, thus highlighting need unravel ICI determinants. The comprehensive analysis ICI-treated patients (n = 509) from Bergonié Institute Profiling (BIP) study (NCT02534649) reveals that mTLSs correlates improved clinical outcomes, independently programmed death ligand 1 (PD-L1) expression genomic features. Employing spatial transcriptomics alongside multiplex immunofluorescence (mIF), we show two distinct cancer-associated fibroblasts (CAFs) essential factors mediating NSCLC. These associated exclusion, exhaustion, increased regulatory infiltration, underscoring TME. Our highlights pivotal role specific thwarting ICIs, proposing new therapeutic targets enhance immunotherapy efficacy.Graphical abstract

Language: Английский

Citations

3
Classifying cancer-associated fibroblasts—The good, the bad, and the target DOI
Lena Cords, Natalie de Souza, Bernd Bodenmiller

et al.

Cancer Cell, Journal Year: 2024, Volume and Issue: 42(9), P. 1480 - 1485

Published: Sept. 1, 2024

Language: Английский

Citations

18
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment DOI
Douglas Hanahan, Olivier Michielin, Mikaël J. Pittet

et al.

Nature reviews. Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 24, 2024

Language: Английский

Citations

13
Prognostic implications and therapeutic opportunities related to CAF subtypes in CMS4 colorectal cancer: insights from single-cell and bulk transcriptomics DOI Creative Commons

Mengke Ma,

Chu Jin, Changhua Zhuo

et al.

APOPTOSIS, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Language: Английский

Citations

2
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop DOI Creative Commons
Chen Zhang,

Wenxin Zhou,

Hai Xu

et al.

Oncogene, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major challenge in the treatment of lung cancer. Cancer associated fibroblasts (CAFs) play key role promoting anti-cancer therapies. This study identified subpopulation CAFs characterized by overexpression collagen triple helix repeat-containing 1 (CTHRC1) through single-cell RNA sequencing cancer patients undergoing EGFR-TKI treatment. These CTHRC1+ were enriched drug-resistant tumors. Mechanistically, enhance glycolytic activity cells activating TGF-β/Smad3 signaling pathway. Excess lactate produced process glycolysis further upregulates CTHRC1 expression histone lactylation, creating positive feedback loop that sustains resistance. The also demonstrated Gambogenic Acid, natural compound, can disrupt this loop, thereby improving efficacy therapy. Additionally, presence tumor tissues could serve as biomarker for predicting response therapy and patient prognosis. Overall, highlights significant suggests targeting be promising strategy overcome drug

Language: Английский

Citations

2
Emerging clinical applications of single-cell RNA sequencing in oncology DOI
Emily Boxer,

Nisan Feigin,

Roi Tschernichovsky

et al.

Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Language: Английский

Citations

1